ZUG, Switzerland , Feb. 16, 2024 (GLOBE NEWSWIRE) Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the extraordinary general meeting of shareholders will take place on Wednesday, March 6, 2024, at 12:00 CST (6:00 a.m. EST). All relevant documents and information relating to the extraordinary general meeting, including the notice and agenda for the extraordinary
The pulmonary arterial hypertension (PAH) treatment industry stands as a beacon of hope for individuals grappling with this rare but serious condition that affects the heart and lungs. PAH involves abnormally high blood pressure in the arteries that connect the heart and lungs, leading to reduced blood flow and stra.
The generic drug market focuses on price. However, multiple generic metformin drugs have been recalled due to poor drug quality. We examine price and quality after these recalls.
ZUG, Switzerland, Oct. 13, 2023 (GLOBE NEWSWIRE) Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of an abstract oral presentation at the Asia Pacific Association of Allergy, Asthma, and Clinical Immunology (APAAACI) and Allergy and Clinical Immunology Society of Singapore (ACIS) APAAACI 2023 International Conference, to be held from October 23-2